---
title: "细胞动力公司董事 Muna Bhanji 报告了普通股的出售"
description: "细胞动力董事 Muna Bhanji 报告处置普通股。细胞动力公司董事 Muna Bhanji 报告了对该公司普通股的处置。完整的文件可以通过以下链接访问"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/240461598.md"
published_at: "2025-05-15T22:52:10.000Z"
---

# 细胞动力公司董事 Muna Bhanji 报告了普通股的出售

> 细胞动力董事 Muna Bhanji 报告处置普通股。细胞动力公司董事 Muna Bhanji 报告了对该公司普通股的处置。完整的文件可以通过以下链接访问

细胞动力董事 Muna Bhanji 报告处置普通股

细胞动力公司董事 Muna Bhanji 报告了对公司普通股的处置。完整的文件可以通过以下链接访问。

### Related Stocks

- [CYTK.US - 细胞动力](https://longbridge.com/zh-CN/quote/CYTK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cytokinetics Reports Aficamten Outperforms Metoprolol in HCM Exercise Capacity Trial | Cytokinetics Incorporated announced new data from the MAPLE-HCM clinical trial, which showed that aficamten outperformed | [Link](https://longbridge.com/zh-CN/news/265150290.md) |
| Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens | Cytokinetics reported a Q3 net loss of $306.2 million, attributed to debt conversion expenses, despite a revenue increas | [Link](https://longbridge.com/zh-CN/news/264497991.md) |
| Pomerantz LLP Issues Reminder to Shareholders in Cytokinetics, Incorporate of Class Action Filing – CYTK | Pomerantz LLP has announced a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud and unlawful  | [Link](https://longbridge.com/zh-CN/news/265405800.md) |
| 03:13 ET
			
			
				CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm | The Schall Law Firm is reminding investors of a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK) f | [Link](https://longbridge.com/zh-CN/news/265287432.md) |
| Class Action Reminder from Pomerantz LLP for Investors of Cytokinetics, Incorporate – CYTK | Pomerantz LLP has filed a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud. Investors are en | [Link](https://longbridge.com/zh-CN/news/265187854.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。